Table 1. Therapies targeting Th17 cells for IBD

Target	Drug	Experimental model or clinical trial status	Effective	Ref
IL-12/23 p40	Ustekinumab	Phase III	Yes	[75]
IL-23p19	Risankizumab	Phase III/II	Yes	[76]
	Brazikumab	Phase III/II	Yes	[77]
	Guselkumab	Phase III/II	Yes	[78]
	Mirikizumab	Phase III/II	Yes	[79]
IL-23 receptor	PTG-200	Phase II/I	Yes	[86]
IL-17A	Secukinumab	Phase II	No	[80]
	Ixekizumab	Phase III	No	[81]
IL-17 receptor	Brodalumab	Phase II	No	[82]
IL-17A/IL-17F/IFN-γ	Vidofludimus	Phase I/II	Yes	[84]
IL-6 trans-signaling	Olamine (sgp130Fc)	Phase II	Yes	[87]
IL-6 receptor	Tocilizumab	Phase II	Yes	[88]
IL-1β	Canakinumab	Phase I(very early onset IBD)	Yes	[89]
IL-1β receptor	Anakinra	Phase II	Yes	[90]
JAK inhibitor	Tofacitinib	FDA approved	Yes	[91]
α4β7	Vedolizumab	FDA approved	Yes	[92]
TNF-α	Infliximab, Adalimumab, Certolizumab	FDA approved	Yes	[93]

Th17, T helper 17; IBD, inflammatory bowel disease; IL, interleukin; IFN, interferon; JAK, Janus kinase; TNF, tumor necrosis factor; FDA, Food and Drug Administration.